{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Continuous Wireless Vital Sign Monitoring in Postoperative Care: A Randomised Controlled Trial"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This randomised controlled trial was conducted in two major university hospitals in Denmark."
      },
      "Participants": {
        "score": 2,
        "evidence": "Adult patients undergoing major noncardiac surgery were randomised 1:1 to standard care or standard care plus continuous wireless monitoring."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Adult patients undergoing major noncardiac surgery were randomised 1:1 to standard care or standard care plus continuous wireless monitoring."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates the impact of continuous wireless vital sign monitoring with real-time alerts on reducing these deviations and complications."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the cumulative duration of severe vital sign deviations per 24 hours."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and outcome assessors were blinded."
      },
      "Blinding": {
        "score": 1,
        "evidence": "outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Between January 2021 and October 2022, 400 patients were randomised (200 intervention, 200 control)."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "400 patients were randomised (200 intervention, 200 control)."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The intervention group had a mean reduction of 47 minutes per day for SpO2 <88% (95% CI, 18\u201380; P = .02)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events occurred in 31.5% of the intervention group versus 42.5% of the control group (P = .03)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ClinicalTrials.gov NCT04640415."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Innovation Fund Denmark (8056-00055B)."
      }
    },
    "total_score": 22,
    "max_score": 25
  },
  "model": "gpt-4o"
}